David Malcom Rodman Sells 25,482 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 25,482 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total value of $382,994.46. Following the completion of the sale, the insider now owns 135,974 shares in the company, valued at approximately $2,043,689.22. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Mineralys Therapeutics Stock Performance

NASDAQ MLYS traded down $0.12 during trading on Friday, reaching $14.04. 329,357 shares of the company’s stock were exchanged, compared to its average volume of 177,844. The company has a 50 day moving average price of $12.87 and a two-hundred day moving average price of $12.58. The stock has a market cap of $698.21 million, a P/E ratio of -5.23 and a beta of 1.71. Mineralys Therapeutics, Inc. has a 1 year low of $5.85 and a 1 year high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.10). During the same period in the previous year, the firm posted ($0.31) earnings per share. Research analysts forecast that Mineralys Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Mineralys Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Mineralys Therapeutics by 0.5% during the first quarter. Vanguard Group Inc. now owns 982,932 shares of the company’s stock worth $12,690,000 after purchasing an additional 4,952 shares during the last quarter. SR One Capital Management LP increased its position in Mineralys Therapeutics by 12.4% during the first quarter. SR One Capital Management LP now owns 2,016,822 shares of the company’s stock worth $26,037,000 after buying an additional 222,222 shares during the period. Affinity Asset Advisors LLC purchased a new stake in Mineralys Therapeutics in the first quarter valued at approximately $4,234,000. Bellevue Group AG acquired a new stake in shares of Mineralys Therapeutics in the first quarter valued at approximately $119,000. Finally, RA Capital Management L.P. increased its holdings in shares of Mineralys Therapeutics by 52.6% in the 1st quarter. RA Capital Management L.P. now owns 4,850,984 shares of the company’s stock valued at $62,626,000 after acquiring an additional 1,672,508 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research note on Thursday, October 31st.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.